CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

Status unconfirmed · Phase 3 · Has a placebo group

Conditions studied: Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy

In brief

This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.

Key facts

Study ID

NCT02504008

Run by

Axsome Therapeutics, Inc.

People needed

190

Starts

2015-07-01

Expected to finish

2019-01-01

Last updated by the study team

2018-03-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Hot Springs, Arkansas, United States
• Study site — Encinitas, California, United States
• Study site — La Jolla, California, United States
• Study site — Los Angeles, California, United States
• Study site — Napa, California, United States
• Study site — Temecula, California, United States
• Study site — Denver, Colorado, United States
• Study site — Clermont, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Canton, Georgia, United States
• Study site — Marietta, Georgia, United States
• Study site — St. Marys, Georgia, United States
• Study site — Meridian, Idaho, United States
• Study site — Chicago, Illinois, United States
• Study site — Louisville, Kentucky, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — New York, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Portland, Oregon, United States
• Study site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.